Transfusion management of hemoglobinopathies;Transfusion sanguine et hémoglobinopathies

Hematologie

Volumn 10, Issue 6, 2004, Pages 470-478

  De Montalembert, Mariane ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Drepanocytosis; Hemoglobinopathy; Thalassemia; Transfusion

Indexed keywords

DEFEROXAMINE; HEMOGLOBIN; HEMOGLOBIN S; HYDROXYUREA; IRON CHELATE;

ALLOIMMUNIZATION; BLOOD GROUP RHESUS SYSTEM; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; BRAIN ARTERY; CEREBROVASCULAR ACCIDENT; DOPPLER ECHOGRAPHY; ERYTHROCYTE CONCENTRATE; HEMOGLOBINOPATHY; INFECTION; IRON OVERLOAD; MORBIDITY; MORTALITY; PHENOTYPE; PROGNOSIS; REVIEW; SICKLE CELL ANEMIA; THALASSEMIA MAJOR;

EID: 13844269163     PISSN: 12647527     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Weatherall DJ, Clegg JB. Thalassemia - a global public health problem. Nat Med 1996; 2: 847-9.
2. Badens C, North ML, Lena-Russo D. Les β-thalassémies en France métropolitaine. Presse Med 2003; 32: 1016-21.
3. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of β-thalassemia major in North America. Blood 2004; 104: 34-9.
4. Rebulla P, Modell B. Transfusion requirements and effects in thalassemia major. Lancet 1991; 337: 277-80.
5. Friedman DF, Jawad AF, Martin MB, Horiuchi K, Mitchell CF, Cohen AR. Erythrocytapheresis to reduce iron loading in thalassemia. Blood 2003; 102: 121a.
6. Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci 1998; 850: 120-8.
7. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe β-thalassemia. Blood 2003; 102: 1529-30.
8. de Montalembert M, Guilloud-Bataille M, Feingold J, Girot R. Epidemiological and clinical study of sickle cell disease in France, French Guiana and Algeria. Eur J Haematol 1993; 51: 136-40.
9. Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 2000; 342: 83-9.
10. Serjeant BE, Hambleton IR, Kerr S, Kilty CG, Serjeant GR. Haematological response to parvovirus B19 infection in homozygous sickle-cell disease. Lancet 2001; 358: 1779-80.
11. Smith-Whitley K, Zhao H, Hodinka RL, Kwiatkowski J, Cecil R, Cecil T, et al. The epidemiology of human parvovirus B19 in children with sickle cell disease. Blood 2004; 103: 422-7.
12. Grover R, Wethers DL. Management of acute splenic sequestration in sickle cell disease. Asso Acad Minor Phys 1990; 1: 67-70.
13. Kinney TR, Ware RE, Schultz WH, Filston HC. Long-terme management of splenic sequestration in children with sickle cell disease. J Pediatr 1990; 117: 194-9.
14. Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood 1993; 81: 1109-23.
15. Siegel JF, Rich MA, Brock WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol 1993; 150: 1480-2.
16. Hassell KL, Eckman JR, Lane PA. Acute multiorgan failure syndrome: a potentially catastrophic complication of severe sickle cell pain episodes. Am J Med 1994; 96: 155-62.
17. Ohene-Frempong K. Indications for red cells transfusion in sickle cell disease. Semin Hematol 2001; 38(Suppl 1): 5-13.
18. Vichinsky EP, Haberkern CM, Neumayr L, Earles AN, Black D, Koshy M, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med 1995; 333: 206-13.
19. Rosse WF, Telen M, Ware RE. Controversies in transfusion in sickle cell disease. In: Rosse WF, Telen M, Ware RE, eds. Transfusion support for patients with sickle cell disease. AABB Press, 1998: 63-71.
20. Hebbel RP, Vercellotti GM. The endothelial biology of sickle cell disease. J Lab Clin Med 1997; 129: 288-93.
21. Belhassen L, Pelle G, Sediame S, Bachir D, Carville C, Bucherer C, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilatation. Blood 2001; 97: 1584-9.
22. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol 1986; 20: 684-94.
23. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler untrasonography. N Engl J Med 1998; 339: 5-11.
24. Ohene-Frempong K, Weiner SJ, Sleeper L, Miller ST, Embury S, Moohr JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91: 288-94.
25. Wang WC, Kovnar EH, Tonkin IL, Mulhern RK, Langston JW, Day SW, et al. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 1991; 118: 377-82.
26. Ware RE, Zimmerman SZ, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 1999; 94: 3022-6.
27. Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, et al. Impact of chronic transfusion on pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001; 139: 785-9.
28. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusion in pregnant patients with sickle cell disease. N Engl J Med 1988; 319: 1447-52.
29. Berkane N, Nizard J, Dreux B, Uzan S, Girot R. Drépanocytose et grossesse. Complications et prise en charge. Path Biol 1999; 47: 46-54.
30. Modell B, Khan M, Darlison M. Survival in β-thalassemia major in the UK: data from the UK Thalassemia register. Lancet 2000; 355: 2051-2.
31. Olivieiri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994; 331: 574-8.
32. Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38(Suppl 1): 30-6.
33. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol 2000; 108: 305-12.
34. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361-4.
35. Kattamis A, Kassou C, Ladis V, Berdoussi H, Papasotiriou I, Kattamis C. Safety and efficay of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia. Blood 2002; 100: 443; [abstract].
36. Piga A, Galanello R, Cappellini MD, Forni GL, Opitz H, Ford JM, et al. Phase II study of oral chelator ICL 670 in thalassemia patients with transfusional iron overload: safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood 2002; 100: 5; [abstract].
37. Hilliard LM, Williams BF, Lounsbury AE, Howard TH. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol 1998; 59: 28-35.
38. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990; 322: 1617-21.
39. Noizat-Pirenne F, Lee K, Pennec PY, Simon P, Kazup P, Bachir D, et al. Rare RHCE phenotypes in black individuals of Afro-caribbean origin: identification and transfusion safety. Blood 2002; 100: 4223-31.
40. Petz LD, Calhoun L, Shulman IA, Johnson C, Herron RM. The sickle cell hemolytic transfusion reaction syndrome. Transfusion 1997; 37: 382-92.
41. Talano JA, Hillery CA, Gottschall JL, Bayelrian DM, Scott JP. Delayed hemolytic transfusion/hyperhemolysis syndrome in children with sickle cell disease. Pediatrics 2003; 11: 661-5.
42. Murad KL, Mahany KL, Brugnara C, Kuypers FA, Eaton JW, Scott MD. Structural and functional consequences of antigenic modulation of red blood cells with methoxypoly (Ethylene Glycol). Blood 1999; 93: 2121-7.
43. de Montalembert M, Costagliola DG, Lefrère JJ, Cornu G, Lombardo T, Cosentino S, et al. Prevalence of markers for human immunodeficiency virus type 1 and 2, human T-lymphotrophic virus type I, cytomegalovirus, and hepatitis B and C virus in multiply transfused thalassemia patients. Transfusion 1992; 32: 509-12.
44. Vichinsky EP. Current issues with blood transfusions in sickle cell disease. Semin Hematol 2001; 38(Suppl 1): 14-22.
45. Pillonel J, Laperche S. Risque résiduel de transmission du VIH, du VHC et du VHB par transfusion sanguine entre 1992 et 2002 en France et impact du dépistage génomique viral. Trans Clin Biol 2004; 11: 81-6.
46. Hartwig D, Schlager F, Bucsky P, Kirchner H, Schlenke P. Successful long-term erythrocytapheresis therapy in a patient with symptomatic sickle-cell disease using an arterio-venous fistula. Transf Med 2002; 12: 75-7.
47. Jeng MR, Feusner J, Skibola C, Vichinsky E. Central venous catheter complications in sickle cell disease. Am J Hematol 2002; 69: 103-8.